1. Safety and efficacy of incobotulinumtoxinA doses up to 800 U in limb spasticity: The TOWER study
- Author
-
Wissel, Jörg, Bensmail, Djamel, Simon, Olivier, Rochford, Edward T. J., Dressler, Dirk, Simpson, David M., TOWER study investigators, McNeil, Stephen, Laffont, Isabelle, Pellas, Frédéric, Dafotakis, Manuel, Ebke, Markus, Ferreira, Joaquim J., Hecht, Martin, Kossmehl, Peter, Liebetanz, David, Müller, Friedemann, Reuter, Iris, Raffauf, Walter, Wächter, Tobias, Barbieri, Sergio, Baricich, Alessio, Basciani, Mario, Molteni, Franco, Ianieri, Giancarlo, Osio, Maurizio, Sciarrini, Francesco, Smania, Nicola, Ader, Tiina, Medeiros, Luisa, Guardiola, Montserrat Abenoza, Pares, Josefina Junyent, López de Munaín, Lourdes, Tirado, Marina, Satkunam, Lalith, Bethoux, François, Bockenek, William, Davé, Shashank, Rubin, Bruce, Moraleda, Susana, Rekand, Tiina, McGuire, John, Scheschonka, Astrid, and Flatau-Baqué, Birgit
- Subjects
Adult ,Lung Diseases ,Male ,030506 rehabilitation ,Adolescent ,incobotulinumtoxinA, limb spasticity ,dose safety ,dose efficacy ,Vital signs ,Article ,Young Adult ,03 medical and health sciences ,Muscle tone ,0302 clinical medicine ,incobotulinumtoxinA ,Humans ,Medicine ,Spasticity ,Botulinum Toxins, Type A ,Young adult ,Adverse effect ,Aged ,Retrospective Studies ,Aged, 80 and over ,Dose-Response Relationship, Drug ,Vital Signs ,business.industry ,Incidence (epidemiology) ,Extremities ,Retrospective cohort study ,Middle Aged ,3. Good health ,medicine.anatomical_structure ,Neuromuscular Agents ,Tolerability ,Muscle Spasticity ,Anesthesia ,Female ,Neurology (clinical) ,limb spasticity ,medicine.symptom ,0305 other medical science ,business ,030217 neurology & neurosurgery - Abstract
Neurology: official journal of the American Academy of Neurology 88(14), 1321-1328 (2017). doi:10.1212/WNL.0000000000003789, Published by Wolters Kluwer, Philadelphia, Pa.
- Published
- 2017
- Full Text
- View/download PDF